European journal of preventive cardiology · 2026
Lipoprotein(a) and long-term revascularization burden: a recurrent-event analysis of the UK Biobank.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cesaro Arturo, Calabrò Paolo, Jamialahmadi Oveis, Pugliese Nicola, Flagiello Valentina, Barreby Emelie, Mancina Rosellina M, Romeo Stefano
Аннотация
AIMS: To investigate whether elevated Lp(a) is independently associated with cumulative coronary, peripheral, and carotid revascularization burden in a primary prevention cohort.
METHODS AND RESULTS: We analysed 237 729 UK Biobank participants of European ancestry free of ASCVD at baseline, followed for a median of 14.1 years. Lp(a) was analysed using the ESC/EAS 2025 threshold of 105 nmol/L and continuously (per 50 nmol/L increment). The primary outcome was the total number of coronary, peripheral, and carotid revascularization procedures per person. Given the genetically determined, lifelong nature of Lp(a) exposure, to capture the full sequence of procedures over time, rather than time-to-first-event alone, we applied recurrent-event statistical models, including the Andersen-Gill model, negative binomial regression, and the Prentice-Williams-Peterson gap-time model. Overall, 10 731 revascularization procedures occurred in 237 729 participants. The proportion undergoing ≥1 procedure was higher with Lp(a) ≥ 105 vs. <105 nmol/L (4.36% vs. 2.96%), with larger differences for ≥2 (1.53% vs. 0.95%) and ≥3 procedures (0.36% vs. 0.18%). In Andersen-Gill analysis, Lp(a) ≥ 105 nmol/L was associated with a higher revascularization rate (HR 1.50, 1.42-1.60), with a 55% higher rate of revascularization procedures during follow-up by negative binomial regression (IRR 1.55, 1.45-1.65). The association was strongest for the first procedure (HR 1.48, 1.40-1.56), attenuated for the second (HR 1.28, 1.09-1.50), and non-significant for the third (HR 1.23, 0.94-1.62). Findings were consistent across coronary and peripheral territories.
CONCLUSION: In this large primary prevention cohort, elevated Lp(a) was independently associated with a higher long-term revascularization burden across multiple vascular territories. The association was robust for coronary, supportive for peripheral, and inconclusive for carotid revascularization owing to limited statistical power. These findings, derived from recurrent-event methodology, provide a more complete quantification of Lp(a)-associated cardiovascular procedural risk than time-to-first-event analyses alone.
METHODS AND RESULTS: We analysed 237 729 UK Biobank participants of European ancestry free of ASCVD at baseline, followed for a median of 14.1 years. Lp(a) was analysed using the ESC/EAS 2025 threshold of 105 nmol/L and continuously (per 50 nmol/L increment). The primary outcome was the total number of coronary, peripheral, and carotid revascularization procedures per person. Given the genetically determined, lifelong nature of Lp(a) exposure, to capture the full sequence of procedures over time, rather than time-to-first-event alone, we applied recurrent-event statistical models, including the Andersen-Gill model, negative binomial regression, and the Prentice-Williams-Peterson gap-time model. Overall, 10 731 revascularization procedures occurred in 237 729 participants. The proportion undergoing ≥1 procedure was higher with Lp(a) ≥ 105 vs. <105 nmol/L (4.36% vs. 2.96%), with larger differences for ≥2 (1.53% vs. 0.95%) and ≥3 procedures (0.36% vs. 0.18%). In Andersen-Gill analysis, Lp(a) ≥ 105 nmol/L was associated with a higher revascularization rate (HR 1.50, 1.42-1.60), with a 55% higher rate of revascularization procedures during follow-up by negative binomial regression (IRR 1.55, 1.45-1.65). The association was strongest for the first procedure (HR 1.48, 1.40-1.56), attenuated for the second (HR 1.28, 1.09-1.50), and non-significant for the third (HR 1.23, 0.94-1.62). Findings were consistent across coronary and peripheral territories.
CONCLUSION: In this large primary prevention cohort, elevated Lp(a) was independently associated with a higher long-term revascularization burden across multiple vascular territories. The association was robust for coronary, supportive for peripheral, and inconclusive for carotid revascularization owing to limited statistical power. These findings, derived from recurrent-event methodology, provide a more complete quantification of Lp(a)-associated cardiovascular procedural risk than time-to-first-event analyses alone.